HALO vs RCL · P/E 15, rev $857.7M vs P/E 26, rev $9.28B
Halozyme Therapeutics Inc (HALO) versus Royal Caribbean Cruises Ltd (RCL) — a side-by-side from cached financials, not a winner call.
Halozyme Therapeutics Inc (HALO) is a biotechnology company listed on US.
Royal Caribbean Cruises Ltd (RCL) is a travel services company listed on US.
Latest reported HALO revenue for 2026-06-30 was $857.7M. Net income was $380.0M. HALO currently screens at market cap $7.10B and trailing P/E 15.3.
Latest reported RCL revenue for 2026-06-30 was $9.28B. Net income was $2.07B. RCL currently screens at market cap $85.57B and trailing P/E 25.7.
HALO currently screens at market cap $7.10B and trailing P/E 15.3. RCL currently screens at market cap $85.57B and trailing P/E 25.7.
Not investment advice. Open the HALO and RCL stock pages for the full models.
Not investment advice.